TD Cowen raised the firm’s price target on TransMedics to $110 from $95 and keeps an Outperform rating on the shares. The firm said they delivered another strong beat-and-raise quarter delivering $52.5M in revenue and increasing 2023 revenue guidance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TMDX:
- TransMedics raises FY23 revenue view to $180M-$190M from $160M-$170M
- TransMedics reports Q2 EPS (3c), consensus (13c)
- TransMedics Reports Second Quarter 2023 Financial Results
- Bridge to Life Divests Certain Assets to TransMedics
- TransMedics Acquires Warm Perfusion EVOSS™ and Cold Perfusion LifeCradle® Technologies from Bridge to Life
